FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285792> ?p ?o ?g. }

• W4379285792 endingPage "609" @default.
• W4379285792 startingPage "609" @default.
• W4379285792 abstract "609 Background: Focal oncogene amplification confers a growth advantage to tumor cells and drives cancer evolution. Herein, we aimed to explore focally amplified HER2 in breast carcinomas. Methods: We performed whole genome sequencing (WGS) and whole-transcriptome sequencing (WTS) in 787 breast cancer samples. HER2 focal amplification was defined as having a segment length less than 3Mbp and ≥4 higher copy number than the surrounding region. Results: Most of the patients were premenopausal women (n = 574, 72.9%) with a median age of 37 (range 21-76) years. We identified 57 (58.8%) and 27 (5.0%) samples with HER2 focal amplification in HER2-positive (n = 97) and even HER2-negative (n = 536) by immunohistochemistry (IHC) and in-situ hybridization (ISH) according to ASCO guideline for breast cancer, respectively. Regardless of HER2-positivity, HER2 focal amplification was significantly associated with higher HER2 RNA expression. Among 28 patients who received six cycles of docetaxel/carboplatin/trastuzumab/pertuzumab neoadjuvant therapy followed by curative surgery, 21 patients had HER2 focal amplification and 14 (66.7%) achieved pathologic complete remission (pCR). Intriguingly, all patients without HER2 focal amplification (n = 7) failed to achieve pCR. HER2 focal amplification showed enrichment of TP53 mutations (OR 0.245, q < 0.001), but was mutually exclusive with GATA3 mutations (OR 2.82, q = 0.055). The mutational spectrums suggested that the activity in APOBEC family of cytidine deaminases were responsible for the somatic single-nucleotide variants of breast cancer with HER2 focal amplification. Compared to samples without HER2 focal amplification, samples with HER2 focal amplification were less likely to have defective homologous recombination DNA repair pathway. HER focal amplifications were closely associated with various types of structural variations. Translocation partners of HER2 were widespread across the entire genome with notable exceptions on chromosome 2, and most of them were close to super-enhancers implying enhancer hijacking as one of mechanisms of HER2 overexpression. Breast cancers with or without HER2 focal amplification showed distinct RNA expression patterns. Notably, activity of genes involved in doxorubicin-resistance and AKT1 signaling were significantly associated with HER2 focal amplification. Conclusions: Our analysis demonstrates that WGS enables better classification of the HER2 amplification status in breast cancer than IHC with ISH, suggesting WGS as a sensitive tool for screening breast cancers for anti-HER2-targeted therapies." @default.
• W4379285792 created "2023-06-05" @default.
• W4379285792 creator A5003412235 @default.
• W4379285792 creator A5010936682 @default.
• W4379285792 creator A5017982180 @default.
• W4379285792 creator A5025187591 @default.
• W4379285792 creator A5028785394 @default.
• W4379285792 creator A5033852351 @default.
• W4379285792 creator A5046809047 @default.
• W4379285792 creator A5049274095 @default.
• W4379285792 creator A5049364024 @default.
• W4379285792 creator A5051636160 @default.
• W4379285792 creator A5055171803 @default.
• W4379285792 creator A5057636290 @default.
• W4379285792 creator A5059131847 @default.
• W4379285792 creator A5062505942 @default.
• W4379285792 creator A5062691447 @default.
• W4379285792 creator A5067205497 @default.
• W4379285792 creator A5068566980 @default.
• W4379285792 date "2023-06-01" @default.
• W4379285792 modified "2023-09-25" @default.
• W4379285792 title "Whole-genome sequencing based assessment of HER2 focal amplification for precision oncology of breast cancers." @default.
• W4379285792 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.609" @default.
• W4379285792 hasPublicationYear "2023" @default.
• W4379285792 type Work @default.
• W4379285792 citedByCount "0" @default.
• W4379285792 crossrefType "journal-article" @default.
• W4379285792 hasAuthorship W4379285792A5003412235 @default.
• W4379285792 hasAuthorship W4379285792A5010936682 @default.
• W4379285792 hasAuthorship W4379285792A5017982180 @default.
• W4379285792 hasAuthorship W4379285792A5025187591 @default.
• W4379285792 hasAuthorship W4379285792A5028785394 @default.
• W4379285792 hasAuthorship W4379285792A5033852351 @default.
• W4379285792 hasAuthorship W4379285792A5046809047 @default.
• W4379285792 hasAuthorship W4379285792A5049274095 @default.
• W4379285792 hasAuthorship W4379285792A5049364024 @default.
• W4379285792 hasAuthorship W4379285792A5051636160 @default.
• W4379285792 hasAuthorship W4379285792A5055171803 @default.
• W4379285792 hasAuthorship W4379285792A5057636290 @default.
• W4379285792 hasAuthorship W4379285792A5059131847 @default.
• W4379285792 hasAuthorship W4379285792A5062505942 @default.
• W4379285792 hasAuthorship W4379285792A5062691447 @default.
• W4379285792 hasAuthorship W4379285792A5067205497 @default.
• W4379285792 hasAuthorship W4379285792A5068566980 @default.
• W4379285792 hasConcept C104317684 @default.
• W4379285792 hasConcept C121608353 @default.
• W4379285792 hasConcept C126322002 @default.
• W4379285792 hasConcept C142724271 @default.
• W4379285792 hasConcept C143998085 @default.
• W4379285792 hasConcept C2779786085 @default.
• W4379285792 hasConcept C48126324 @default.
• W4379285792 hasConcept C49105822 @default.
• W4379285792 hasConcept C502942594 @default.
• W4379285792 hasConcept C530470458 @default.
• W4379285792 hasConcept C54355233 @default.
• W4379285792 hasConcept C71924100 @default.
• W4379285792 hasConcept C7602840 @default.
• W4379285792 hasConcept C86803240 @default.
• W4379285792 hasConceptScore W4379285792C104317684 @default.
• W4379285792 hasConceptScore W4379285792C121608353 @default.
• W4379285792 hasConceptScore W4379285792C126322002 @default.
• W4379285792 hasConceptScore W4379285792C142724271 @default.
• W4379285792 hasConceptScore W4379285792C143998085 @default.
• W4379285792 hasConceptScore W4379285792C2779786085 @default.
• W4379285792 hasConceptScore W4379285792C48126324 @default.
• W4379285792 hasConceptScore W4379285792C49105822 @default.
• W4379285792 hasConceptScore W4379285792C502942594 @default.
• W4379285792 hasConceptScore W4379285792C530470458 @default.
• W4379285792 hasConceptScore W4379285792C54355233 @default.
• W4379285792 hasConceptScore W4379285792C71924100 @default.
• W4379285792 hasConceptScore W4379285792C7602840 @default.
• W4379285792 hasConceptScore W4379285792C86803240 @default.
• W4379285792 hasIssue "16_suppl" @default.
• W4379285792 hasLocation W43792857921 @default.
• W4379285792 hasOpenAccess W4379285792 @default.
• W4379285792 hasPrimaryLocation W43792857921 @default.
• W4379285792 hasRelatedWork W1722328147 @default.
• W4379285792 hasRelatedWork W2066747782 @default.
• W4379285792 hasRelatedWork W2560406314 @default.
• W4379285792 hasRelatedWork W2593475799 @default.
• W4379285792 hasRelatedWork W2627001382 @default.
• W4379285792 hasRelatedWork W2751941543 @default.
• W4379285792 hasRelatedWork W2896532861 @default.
• W4379285792 hasRelatedWork W2934076975 @default.
• W4379285792 hasRelatedWork W4242374293 @default.
• W4379285792 hasRelatedWork W2342209702 @default.
• W4379285792 hasVolume "41" @default.
• W4379285792 isParatext "false" @default.
• W4379285792 isRetracted "false" @default.
• W4379285792 workType "article" @default.